Business Context and Reporting Period
This Form 8-K Current Report, dated March 12, 2003, covers Harvard Bioscience, Inc. (HBIO) and its wholly-owned subsidiary, Genomic Solutions Inc. The report details the completion of an asset acquisition on March 12, 2003.
Key Financial Metrics
- Acquisition Cost: Approximately $8.1 million in cash plus the assumption of certain specified liabilities.
- Escrow Amount: $2,071,000 deposited by the seller to secure indemnification obligations, held for 18 months.
- Funding Source: General working capital and proceeds from a bridge loan with Brown Brothers Harriman & Co.
- Accounting Treatment: The transaction will be accounted for as a purchase.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.
- Debt and Liquidity: Specific debt levels and liquidity ratios are not disclosed in this filing.
Material Changes
The primary material change is the acquisition of substantially all assets of Genomic Instrumentation Services, Inc. (d/b/a GeneMachines). GeneMachines specializes in high-throughput instrumentation for DNA and protein microarray production, nucleic acid sample preparation, and DNA synthesis. Genomic Solutions intends to continue using these assets and will distribute its genomic product line globally under the "GeneMachines" brand name.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the integration of GeneMachines assets and future distribution plans. Management disclaims any obligation to update these statements. The report references known and unknown risks detailed in the Company's 2001 Form 10-K and Form S-4 filings that could cause actual results to differ materially from anticipated outcomes. Pro forma financial information and financial statements of the acquired business are not included in this filing but are scheduled to be filed by amendment no later than May 26, 2003.
Investor Verification Checklist
- Verify the specific amount of liabilities assumed in the acquisition, as the filing states "certain specified liabilities" without a total figure.
- Review the upcoming amendment (due by May 26, 2003) for the financial statements of GeneMachines and pro forma financial information.
- Assess the impact of the bridge loan with Brown Brothers Harriman & Co. on the company's overall debt load and interest expenses.
- Confirm the terms of the 18-month escrow arrangement and the conditions for releasing the $2,071,000.